Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00614653
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    5 mg/kg IV Over 90 Minutes Every 2 Weeks
  • Erlotinib — DRUG
    100 mg by mouth Once Daily on days with radiation.
  • Capecitabine — DRUG
    400 mg/m\^2 PO Twice Daily on days with radiation.
  • Radiation Therapy — RADIATION
    Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy

Study Details

The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.

Key Dates

First listed
Feb 13, 2008
Start date
Jan 31, 2008
Status verified
Jul 2016
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab, Erlotinib + Capecitabine
    Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.

Primary Outcome Measure

Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation [ Time Frame: 5 1/2 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies